Myriad gets $14.2 million for pathogen drug/diagnostic:
This article was originally published in Clinica
Myriad Genetics has been awarded a five-year, $14.2m contract by the US National Institutes of Health for work that could lead to the development of products that focus on microorganisms and pathogens. The Salt Lake City, Utah firm says it will use its expertise to characterise pathogen-host protein interactions in an effort to discover targets for the next generation of vaccines, therapeutics and diagnostics. Protein interaction and validation data will be made available to the research and development community through the Proteomics Research Program Administrative Center. Myriad says it retains the rights to commercialise diagnostic and therapeutic targets discovered from the project.
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.